Evidence map›Paper›PMID 36507364›Full record

SynthesisFrontiers in neuroscience2022

Neuroprotective effect of Src kinase in hypoxia-ischemia: A systematic review.

Panagiotis Christidis, Abhya Vij, Stamatios Petousis, Javid Ghaemmaghami, Bhairav V Shah, Ioannis Koutroulis, Panagiotis Kratimenos

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Panagiotis ChristidisLaboratory of Physiology, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Abhya VijDepartment of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.
Stamatios Petousis2nd Department of Obstetrics and Gynecology, "Hippokrateion" General Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Javid GhaemmaghamiCenter for Neuroscience Research, Children's National Research Institute, Washington, DC, United States.
Bhairav V ShahDivision of Pediatric Surgery, Department of Pediatrics, School of Medicine, Prisma Health Children's Hospital-Midlands, University of South Carolina, Columbia, SC, United States.
Ioannis KoutroulisDepartment of Pediatrics, Division of Emergency Medicine, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC, United States.
Panagiotis KratimenosCenter for Neuroscience Research, Children's National Research Institute, Washington, DC, United States.
Children's National · USAristotle University of Thessaloniki · GRGeorge Washington University · USHarvard University · USIppokrateio General Hospital of Thessaloniki · GRPrisma Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hypoxic-ischemic encephalopathy (HIE) is a major cause of neonatal morbidity and mortality worldwide. While the application of therapeutic hypothermia has improved neurodevelopmental outcomes for some survivors of HIE, this lone treatment option is only available to a subset of affected neonates. Src kinase, an enzyme central to the apoptotic cascade, is a potential pharmacologic target to preserve typical brain development after HIE. Here, we present evidence of the neuroprotective effects of targeting Src kinase in preclinical models of HIE. Methods: We performed a comprehensive literature search using the National Library of Medicine's MEDLINE database to compile studies examining the impact of Src kinase regulation on neurodevelopment in animal models. Each eligible study was assessed for bias. Results: Twenty studies met the inclusion criteria, and most studies had an intermediate risk for bias. Together, these studies showed that targeting Src kinase resulted in a neuroprotective effect as assessed by neuropathology, enzymatic activity, and neurobehavioral outcomes. Conclusion: Src kinase is an effective neuroprotective target in the setting of acute hypoxic injury. Src kinase inhibition triggers multiple signaling pathways of the sub-membranous focal adhesions and the nucleus, resulting in modulation of calcium signaling and prevention of cell death. Despite the significant heterogeneity of the research studies that we examined, the available evidence can serve as proof-of-concept for further studies on this promising therapeutic strategy.

Indexed as

hypoxiahypoxic-ischemic encephalopathy (HIE)neonatal brainneuroprotectionSrc

Identifiers

PMID36507364
PMCPMC9730728
OpenAlexW4309857308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.